TEVA

AlphaInsight Score 84/100

Teva Pharmaceutical Industries Limited · Health Care

84
AlphaInsight Score
Momentum86
Valuation78
Growth74
Safety70

Teva Pharmaceutical is a global generic and specialty pharmaceutical powerhouse leading in complex formulations and biosimilars. The stock is currently powered by its 'Pivot to Growth' strategy, driven by AUSTEDO and AJOVY commercial strength alongside pipeline progress with anti-TL1A therapy.

Market cap
$22B
P/E ratio
13.2
EPS growth
18.0%
Revenue growth
9.2%
Dividend yield
0.0%
Beta (5Y)
0.85
RSI (14)
62

The AlphaInsight Score is a proprietary 0–100 composite of momentum, valuation, growth and safety factors. Research snapshot updated 2026-09-05.

Bull case

AUSTEDO continues to capture substantial share in tardive dyskinesia and chorea, tracking toward multi-billion-dollar peak sales. Duvakitug (anti-TL1A partnered with Sanofi) offers substantial upside in inflammatory bowel disease, representing a major novel pipeline driver. Debt loads have decreased markedly, unlocking multiple expansion as litigation overhangs recede.

Bear case

Commodity generic markets in the US and Europe remain vulnerable to periodic pricing headwinds and manufacturing compliance hurdles. Substantial outstanding debt obligations still constrain aggressive shareholder return initiatives relative to peers. Looming competition in migraine and movement disorders could moderate specialty franchise growth.

TEVA FAQ

What is the AlphaInsight Score for TEVA?

Teva Pharmaceutical Industries Limited scores 84/100 on the AlphaInsight Score — ranked #29 of 656 stocks in our research universe. It blends momentum (86/100), valuation (78/100), growth (74/100) and safety (70/100).

Is TEVA a buy right now?

TEVA currently carries an AlphaInsight Score of 84/100 in our research system. Subscribers receive daily entry, target and stop-loss levels whenever it appears in a slate.

What are the biggest risks with TEVA?

Commodity generic markets in the US and Europe remain vulnerable to periodic pricing headwinds and manufacturing compliance hurdles. Substantial outstanding debt obligations still constrain aggressive shareholder return initiatives relative to peers. Looming competition in migraine and movement disorders could moderate specialty franchise growth.

How does TEVA compare to its peers?

Compare TEVA head-to-head with VTRS, OGN, NBIX on AlphaInsight Scores, valuation, growth and safety factors.

Get the full research on TEVA

Subscribers get the complete thesis, risk factors and technical breakdown for TEVAand 10 researched ideas every trading day.

Cancel anytime · Secure checkout

Cite & share this research

Ready-to-paste citation snippets for forums, Reddit, X or your own site.

Markdown (Reddit, X, forums)
[TEVA stock research — AlphaInsight Score & technical signals](https://alphainsightai.net/stocks/TEVA)
HTML (websites, blogs)
<a href="https://alphainsightai.net/stocks/TEVA">TEVA stock research — AlphaInsight Score & technical signals</a>
Alpha Insight AI provides AI-generated analysis for informational purposes only and is not investment advice. All investing involves risk, including the possible loss of principal.